Compare Mercadolibre Inc (MELI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs BIO-TECHNE Corp — how do they compare? Mercadolibre Inc trades at $1,816.94 (market cap $92.90B), while BIO-TECHNE Corp trades at $71.71 (market cap $11.16B). The key difference: Mercadolibre Inc is far larger — about 8.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| MELI | TECH | |
|---|---|---|
Market Cap | $92.90B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.51K | $72.12 |
52-Week Low | $1.55K | $43.31 |
Enterprise Value | $99.79B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,832.29, up 1.01% in the last session, while showing a bearish technical signal overall. The company reported strong revenue growth, with 2025 revenue reaching $28.89 billion, though recent quarterly EPS results have missed expectations. Operating cash flow improved significantly to $12.12 billion in 2025, and analyst sentiment remains strongly positive with a consensus price target of $2,230.
The outlook for MELI is supported by robust top-line expansion and strategic investments in logistics and fintech, but near-term margin pressure and recent earnings misses present risks. The stock offers growth potential in Latin American e-commerce and digital payments, balanced by competitive and execution challenges in a dynamic market environment.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
